Voloridge Investment Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,807,279
| Closed | -$245M | – | 1197 |
|
|
2025
Q4 | $245M | Buy |
4,807,279
+4,302,126
| +852% | +$220M | 0.86% | 11 |
|
|
2025
Q3 | $28M | Buy |
505,153
+477,622
| +1,735% | +$28M | 0.09% | 260 |
|
|
2025
Q2 | $1.9M | Sell |
27,531
-1,723,476
| -98% | -$117M | 0.01% | 958 |
|
|
2025
Q1 | $122M | Buy |
1,751,007
+298,835
| +21% | +$24.7M | 0.45% | 39 |
|
|
2024
Q4 | $125M | Buy |
1,452,172
+833,966
| +135% | +$90.2M | 0.44% | 36 |
|
|
2024
Q3 | $73.6M | Buy |
+618,206
| New | +$82.4M | 0.27% | 90 |
|
|
2024
Q2 | – | Sell |
-52,788
| Closed | -$6.78M | – | 1325 |
|
|
2024
Q1 | $6.78M | Buy |
+52,788
| New | +$6.28M | 0.02% | 574 |
|
|
2023
Q4 | – | Sell |
-748,057
| Closed | -$68M | – | 1374 |
|
|
2023
Q3 | $68M | Sell |
748,057
-8,445
| -1% | -$744K | 0.34% | 73 |
|
|
2023
Q2 | $61.2M | Buy |
756,502
+10,622
| +1% | +$868K | 0.29% | 82 |
|
|
2023
Q1 | $59.3M | Sell |
745,880
-135,144
| -15% | -$9.58M | 0.3% | 80 |
|
|
2022
Q4 | $59.6M | Buy |
881,024
+308,948
| +54% | +$18.1M | 0.33% | 60 |
|
|
2022
Q3 | $28.5M | Buy |
572,076
+290,648
| +103% | +$15.6M | 0.15% | 187 |
|
|
2022
Q2 | $15.7M | Buy |
+281,428
| New | +$15.6M | 0.08% | 324 |
|
|
2022
Q1 | – | Sell |
-176,500
| Closed | -$9.88M | – | 1606 |
|
|
2021
Q4 | $9.88M | Buy |
176,500
+156,818
| +797% | +$8.5M | 0.05% | 473 |
|
|
2021
Q3 | $945K | Buy |
+19,682
| New | +$952K | 0.01% | 1300 |
|
|
2020
Q4 | – | Sell |
-195,974
| Closed | -$6.8M | – | 1493 |
|
|
2020
Q3 | $6.8M | Buy |
195,974
+65,928
| +51% | +$2.2M | 0.06% | 359 |
|
|
2020
Q2 | $4.26M | Sell |
130,046
-122,630
| -49% | -$3.91M | 0.05% | 397 |
|
|
2020
Q1 | $7.61M | Sell |
252,676
-196,036
| -44% | -$5.84M | 0.22% | 103 |
|
|
2019
Q4 | $13M | Buy |
448,712
+275,606
| +159% | +$7.63M | 0.25% | 89 |
|
|
2019
Q3 | $4.47M | Buy |
173,106
+107,630
| +164% | +$2.72M | 0.08% | 281 |
|
|
2019
Q2 | $1.67M | Buy |
+65,476
| New | +$1.62M | 0.05% | 358 |
|
|
2018
Q4 | – | Sell |
-34,526
| Closed | -$814K | – | 460 |
|
|
2018
Q3 | $814K | Sell |
34,526
-323,916
| -90% | -$7.9M | 0.02% | 232 |
|
|
2018
Q2 | $8.27M | Buy |
358,442
+216,010
| +152% | +$5.13M | 0.22% | 107 |
|
|
2018
Q1 | $3.51M | Sell |
142,432
-113,704
| -44% | -$2.99M | 0.08% | 212 |
|
|
2017
Q4 | $6.87M | Buy |
+256,136
| New | +$6.51M | 0.15% | 158 |
|
|
2017
Q2 | – | Sell |
-188,048
| Closed | -$3.22M | – | 524 |
|
|
2017
Q1 | $3.22M | Buy |
+188,048
| New | +$3.27M | 0.08% | 269 |
|
|
2015
Q3 | – | Sell |
-128,728
| Closed | -$3.52M | – | 369 |
|
|
2015
Q2 | $3.52M | Buy |
+128,728
| New | +$3.62M | 0.18% | 130 |
|
Other funds holding NVO
DAM
F
Voloridge Investment Management's NVO Position: Q1 2026 in Review
Voloridge Investment Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 4,807,279 shares — an estimated $245M sold.
Voloridge Investment Management first reported a position in NVO in Q2 2015 and held it in 27 quarters. The position peaked at $245M in Q4 2025. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Voloridge Investment Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
- Voloridge Investment Management sold 4,807,279 Novo Nordisk shares in Q1 2026, an estimated $245M.
- Voloridge Investment Management first reported a position in Novo Nordisk in Q2 2015 and held it in 27 quarters.
- Voloridge Investment Management's Novo Nordisk position peaked at $245M in Q4 2025.
- 1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.